Biogen's (BIIB +0.9%) Tecfidera may be stealing some thunder from Novartis' (NVS -0.6%) Gilenya,...


Biogen's (BIIB +0.9%) Tecfidera may be stealing some thunder from Novartis' (NVS -0.6%) Gilenya, Wells Fargo's Brian Abrahams says, noting that U.S. Gilenya sales came in at $255M for Q2 (from slide 37 of the Q2 presentation) representing just 5% Q/Q growth compared to a historical average of 13%. Abrahams was out earlier this month with bullish commentary on Tecfidera's W/W sales growth.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs